Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Cullen

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|February 14, 2006
Second-line treatment options in advanced non-small cell lung cancer: current statusMichael Cullen
British Journal of Sports Medicine|February 7, 2001
CommentaryMichael Cullen
Open Access Journal of Sports Medicine|November 8, 2013
Developing a new specialty - sport and exercise medicine in the UKMichael Cullen
Trends in Genetics : TIG|March 26, 2004
Justified chauvinism: advances in defining meiotic recombination through sperm typingMary Carrington, Michael Cullen
Current Opinion in Oncology|May 25, 2006
The prevention of febrile neutropeniaJennifer Pascoe, Michael Cullen
The Lancet. Oncology|February 6, 2004
Clinical trials with moving targets: a commentary on a non-inferiority trial in testicular cancerMichael Cullen, Sally Stenning
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Potential hazards in the analysis of symptom improvementLucinda Billingham, Michael Cullen
Current Opinion in Oncology|July 20, 2002
Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancerLouise Medley, Michael Cullen
Hematological Oncology|June 20, 2006
Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsiderNangi Lo, Michael Cullen
Lancet (London, England)|November 26, 2008
Gefitinib or docetaxel in advanced non-small-cell lung cancerMichael Cullen, Nicholas Thatcher
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|February 14, 2006
Second-line treatment options in advanced non-small cell lung cancer: current statusMichael Cullen
British Journal of Sports Medicine|February 7, 2001
CommentaryMichael Cullen
Open Access Journal of Sports Medicine|November 8, 2013
Developing a new specialty - sport and exercise medicine in the UKMichael Cullen
Trends in Genetics : TIG|March 26, 2004
Justified chauvinism: advances in defining meiotic recombination through sperm typingMary Carrington, Michael Cullen
Current Opinion in Oncology|May 25, 2006
The prevention of febrile neutropeniaJennifer Pascoe, Michael Cullen
The Lancet. Oncology|February 6, 2004
Clinical trials with moving targets: a commentary on a non-inferiority trial in testicular cancerMichael Cullen, Sally Stenning
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Potential hazards in the analysis of symptom improvementLucinda Billingham, Michael Cullen
Current Opinion in Oncology|July 20, 2002
Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancerLouise Medley, Michael Cullen
Hematological Oncology|June 20, 2006
Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsiderNangi Lo, Michael Cullen
Lancet (London, England)|November 26, 2008
Gefitinib or docetaxel in advanced non-small-cell lung cancerMichael Cullen, Nicholas Thatcher
Pageof 9